anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Kaletra Adherence Support Assistance (KASA) Program is a customized support network that has been offered to patients treated with lopinavir / ritonavir (LPV/r; Kaletra®). KASA offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events. Patients enrolled in KASA may also have access to various healthcare professionals (dietician, social worker, psychologist, etc.) or may be offered other types of support (transportation, exercise, etc.), which may help improve their quality of life as well as adherence or compliance while taking LPV/r.

This was a 12-month, multi-center, Canadian Post Marketing Observational Study utilizing a prospective single cohort design. All treatments including participation in the KASA program were according to the decision of the treating physician and the patients and were not affected in any way by their decision to participate in the study. Follow-up was for 12 months at an interval of every six months.
OBJECTIVE: Sustained clinical and hemodynamic benefit after revascularization for chronic limb-threatening ischemia (CLTI) is needed to resolve symptoms and prevent limb loss. We sought to compare rates of clinical and hemodynamic failure as well as resolution of initial and prevention of recurrent CLTI after endovascular (ENDO) vs bypass (OPEN) revascularization in the Best-Endovascular-versus-best-Surgical-Therapy-in-patients-with-CLTI (BEST-CLI) trial.
METHODS: As planned secondary analyses of the BEST-CLI trial, we examined the rates of (1) clinical failure (a composite of all-cause death, above-ankle amputation, major reintervention, and degradation of WIfI stage); (2) hemodynamic failure (a composite of above-ankle amputation, major and minor reintervention to maintain index limb patency, failure to an initial increase or a subsequent decrease in ankle brachial index of 0.15 or toe brachial index of 0.10, and radiographic evidence of treatment stenosis or occlusion); (3) time to resolution of presenting CLTI symptoms; and (4) incidence of recurrent CLTI. Time-to-event analyses were performed by intention-to-treat assignment in both trial cohorts (cohort 1: suitable single segment great saphenous vein [SSGSV], N = 1434; cohort 2: lacking suitable SSGSV, N = 396), and multivariate stratified Cox regression models were created.
RESULTS: In cohort 1, there was a significant difference in time to clinical failure (log-rank P < .001), hemodynamic failure (log-rank P < .001), and resolution of presenting symptoms (log-rank P = .009) in favor of OPEN. In cohort 2, there was a significantly lower rate of hemodynamic failure (log-rank P = .006) favoring OPEN, and no significant difference in time to clinical failure or resolution of presenting symptoms. Multivariate analysis revealed that assignment to OPEN was associated with a significantly lower risk of clinical and hemodynamic failure in both cohorts and a significantly higher likelihood of resolving initial and preventing recurrent CLTI symptoms in cohort 1, including after adjustment for key baseline patient covariates (end-stage renal disease [ESRD], prior revascularization, smoking, diabetes, age >80 years, WIfI stage, tissue loss, and infrapopliteal disease). Factors independently associated with clinical failure included age >80 years in cohort 1 and ESRD across both cohorts. ESRD was associated with hemodynamic failure in cohort 1. Factors associated with slower resolution of presenting symptoms included diabetes in cohort 1 and WIfI stage in cohort 2.
CONCLUSIONS: Durable clinical and hemodynamic benefit after revascularization for CLTI is important to avoid persistent and recurrent CLTI, reinterventions, and limb loss. When compared with ENDO, initial treatment with OPEN surgical bypass, particularly with available saphenous vein, is associated with improved clinical and hemodynamic outcomes and enhanced resolution of CLTI symptoms.
In addition to the informative brochure prepared by the researcher, a 6-session motivational interview-based training program will be given. The training program will include topics such as nutrition, physical activity, smoking and alcohol use.
3p deletion syndrome or deletion 3p25-pter syndrome is an exceptionally rare genetic disorder characterized by deletion of the distal segment of the short arm of chromosome 3. There are less than a hundred reported cases worldwide. Clinical characteristics include severe physical and mental retardation, trigonocephaly, micrognathia, and diffuse hypotonia. The common ocular manifestations include congenital ptosis and canthal anomalies. To the best of the authors' knowledge, no lacrimal drainage anomalies have been reported earlier. The present case describes proximal lacrimal drainage anomalies in a patient with 3p deletion syndrome. The patient was successfully managed with membranotomy and punctal and canalicular dilatation, resulting in a complete resolution of epiphora.
Subjects will be randomized into two groups. In the control group, the treating physician will not see the blood volume measurement results. In the experimental group, the physician will be given the blood volume measurement results. Ultrafiltration is performed based on the results of blood volume measurement in the experimental group followed by repeat blood volume analysis after 30 minutes of the completion of ultrafiltration. Clinical and laboratory assessment as per the standard of care will be used to assess overall fluid status, and blood volume measurement results will be used as the assessment of intravascular fluid. These assessments will be used to determine a goal quantity of fluid to be removed. All subjects will return for a clinical assessment at 30 and 90 days and laboratory data will be drawn at that time to evaluate renal functional indices, electrolytes and blood volume measurements.
There will be an enhanced EHR alert, known as a Best Practice Advisory \[BPA\], which will appear on each provider's EHR screen. We will add a boostering option in the enhanced BPA, which is a provider-directed option for a follow-up in-basket message sent 4 weeks after the BPA is triggered.
FIELD: medicine. SUBSTANCE: method involves administering balneotherapy with 10-12 general purpose sodium chloride baths at 36-37 C during 10-15 min included into treatment course. The first 6 baths are administered every other day and the rest of them daily. Compresses containing 1-2% Tonus plus preparation solution are applied for 2-3 h to articulations injured by reactive synovitis or low frequency magnetotherapy is applied. Biologically active nutrient additive is administered at a dose of 1 drop in the morning and at daytime daily. Massage and medical training exercises are prescribed. EFFECT: stable anti inflammatory and immunocorrection effect; prevented recidivation. 7 tbl
You will receive only iGetBetter for the 3 months preceding surgery. After surgery, you will receive only home physical therapy, and will not use iGetBetter. After those three weeks, you will receive outpatient physical therapy approximately twice per week for the next 6-8 weeks.
1,200,256. Magnesium calcium hydroxycarbonate or carbonate. MERCK & CO. Inc. 4 July, 1968 [7 July, 1967 ; 17 June, 1968], No. 31941/68. Heading C1A. [Also in Division A5] Compositions containing magnesium calcium hydroxy carbonate co-form or magnesium calcium carbonate co-form the co-forms having a molar composition xMgO : yCaO where x and y each represent an integer from 1 to 5, preferably x being different from y, are prepared by either carbonating an aqueous slurry containing Ca(OH) 2  with CO 2  until a pH of 4À5-6À5 is obtained, blending the carbonated slurry with an aqueous slurry of Mg(OH) 2 , separating and washing and drying the solids so obtained or by blending aqueous slurries of Mg(OH) 2  and Ca(OH) 2 , carbonating the mixture with CO 2  until a pH of 6À5-9À5 is obtained, heating to expand the material, separating and drying drying the solid so obtained. The magnesium calcium carbonate co-form may also be prepared by reacting a solution containing MgCl 2  and CaCl 2  with an excess of Na 2 CO 3 , heating the resulting slurry and separating the solids. The carbonates or hydroxy carbonate co-forms may be used as aspirin solubilizing agents. (See Division A5).
Indirect pulp treatment is a procedure in which pulp exposure is prevented by preserving the carious dentin bordering the pulp and sealing the pulp with a biocompatible material. . Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect. However, several disadvantages were reported with its use over time including poor seal, lack of chemical and mechanical adhesion, poor strength, long-term solubility, enhanced degradation after acid etching and tunnel defects in the dentin bridge . The operative tradition is to remove softened dentin to eliminate infected tissue; however, it is impossible to eradicate all the micro-organisms because few will persist although all soft dentin was excavated.

Evidence suggest that for arresting caries lesions, it is not crucial to completely remove the infected dentin and that selective caries removal and composite restoration can yield better clinical results . For more conservative and effective treatment, disinfection instead of complete caries removal has been encouraged. . PAD is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens . The usage of PAD in caries management can eradicate residual bacteria in soft dentin, reassures rapid healing and improve the prognosis of treatment .
Hallucinations and perceptual abnormalities in psychosis are thought to arise from imbalanced integration of prior information and sensory inputs. We combined psychophysics, Bayesian modeling, and electroencephalography (EEG) to investigate potential changes in perceptual and causal inference in response to audiovisual flash-beep sequences in medicated individuals with schizophrenia who exhibited limited psychotic symptoms. Seventeen participants with schizophrenia and 23 healthy controls reported either the number of flashes or the number of beeps of audiovisual sequences that varied in their audiovisual numeric disparity across trials. Both groups balanced sensory integration and segregation in line with Bayesian causal inference rather than resorting to simpler heuristics. Both also showed comparable weighting of prior information regarding the signals' causal structure, although the schizophrenia group slightly overweighted prior information about the number of flashes or beeps. At the neural level, both groups computed Bayesian causal inference through dynamic encoding of independent estimates of the flash and beep counts, followed by estimates that flexibly combine audiovisual inputs. Our results demonstrate that the core neurocomputational mechanisms for audiovisual perceptual and causal inference in number estimation tasks are largely preserved in our limited sample of medicated post-acute individuals with schizophrenia. Future research should explore whether these findings generalize to unmedicated patients with acute psychotic symptoms.
Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
The standard method for the quantification of anti-influenza antibodies, a method for inhibiting the hemagglutination, requires the use of erythrocytes and viral particles. The aforementioned characteristic makes difficult the implementation of the method. The present invention presents a novel immunological method (ELISA type) for diagnosing the presence, concentration or titre of anti Influenza A/H1N1/2009 antibodies in samples of blood serum or plasma in human subjects or animal models such as ferrets, rats, mice, amongst others. The proposed method does not require the use of viral particles or virus. The main component of the diagnosis method is a protein, referred in the invention as HA50-274-h1n1. Said protein is a fragment of the Hemagglutinin protein of the Influenza A H1n1/2009 virus expressed in Escherichia coli strains. In its recommended version, the diagnosis method of the present invention comprises fixing an anti histidine antibody to the surface of the diagnosis devic e; blocking the remaining spaces in the surface of the device with a protein or other blocking agent; adding the protein HA50-274-H1N1; adding a sample of the problem serum diluted in a PBS solution at a ratio of 1:50; adding an anti IgG antibody bonded to peroxidase; adding a substrate for the peroxidation reaction; evaluating the occurrence degree of the reaction by absorbance readings at 580 nm. This method may be used for the evaluation of anti Influenza A/H1N1 antibody titres in applications related to the development of vaccines against Influenza, epidemiologic studies based on serology, in studies for determining the susceptibility to be infected by Influenza A/H1N1, etc. The inventive method is particularly useful for evaluating samples taken from the third post-infection week.
Patellofemoral pain syndrome is due to dysfunctional dynamic knee valgus resulting from decrease in strength of hip abductors or abnormal rear-foot eversion with pes pronatus valgus. It is also associated with vastus medialis/vastus lateralis disbalance, hamstring tightness or iliotibial tract tightness. The pain is felt around or behind the patella. The causes are multifactorial. A decline in ability to perform physical activity is seen. The aim of this study will be to compare the effects of concentric and eccentric exercises on pain, strength and ROM in patellofemoral pain syndrome.A randomized clinical trial will be performed at Barki Advance Physiotherapy Center Multan through convenience sampling technique on 24 patients which will be allocated through random sampling through sealed opaque enveloped into group A and group B. Group A will receive eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training. The group B will receive concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM. Screening tools include patellar grind test with positive Clark's sign and VAS (visual analogue scale) for pain rating. Outcomes will be measured through knee resisted test and MMT grading for knee extensor/flexor strength and goniometer for ROM. Data will be analyzed using SPSS software version 25. After assessing normality, it will be decided either parametric or non parametric test will be used within a group or between two groups. Effectiveness of concentric and eccentric exercises will be analyzed by comparison in individuals with patellofemoral pain syndrome.
Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
BACKGROUND AND AIMS: Cell death and inflammation play critical roles in chronic tissue damage caused by cholestatic liver injury leading to fibrosis and cirrhosis. Liver cirrhosis is often associated with kidney damage, which is a severe complication with poor prognosis. Interferon regulatory factor 3 (IRF3) is known to regulate apoptosis and inflammation, but its role in cholestasis remains obscure. In this study.
APPROACH AND RESULTS: We discovered increased IRF3 phosphorylation in the liver of patients with primary biliary cholangitis and primary sclerosing cholangitis. In the bile duct ligation model of obstructive cholestasis in mice, we found that tissue damage was associated with increased phosphorylated IRF3 (p-IRF3) in the liver and kidney. IRF3 knockout ( Irf3-/- ) mice showed significantly attenuated liver and kidney damage and fibrosis compared to wide-type mice after bile duct ligation. Cell-death pathways, including apoptosis, necroptosis, and pyroptosis, inflammasome activation, and inflammatory responses were significantly attenuated in Irf3-/- mice. Mechanistically, we show that bile acids induced p-IRF3 in vitro in hepatocytes. In vivo , activated IRF3 positively correlated with increased expression of its target gene, Z-DNA-Binding Protein-1 (ZBP1), in the liver and kidney. Importantly, we also found increased ZBP1 in the liver of patients with primary biliary cholangitis and primary sclerosing cholangitis. We discovered that ZBP1 interacted with receptor interacting protein 1 (RIP1), RIP3, and NLRP3, thereby revealing its potential role in the regulation of cell-death and inflammation pathways. In conclusion.
CONCLUSIONS: Our data indicate that bile acid-induced p-IRF3 and the IRF3-ZBP1 axis play a central role in the pathogenesis of cholestatic liver and kidney injury.
Endoscopic endonasal surgery (EES) is widely employed for interventions in skull base. Despite advancements in surgical techniques, cerebrospinal fluid (CSF) leakage remains a significant concern. The introduction of nasoseptal flap (NSF) dramatically reduced the CSF leakage rates, yet reconstruction techniques continue to vary among institutions and lack standardization. Recently, injectable hydroxyapatite (HA), traditionally used in open skull base reconstruction, has been adapted for use in EES. This study compares the effectiveness of HA and NSF reconstruction with the standard multilayer NSF reconstruction alone. We searched for eligible studies in PubMed, Embase, and Cochrane Library. CSF leakage rates and reconstruction-associated complication rates were thoroughly evaluated. We initially reviewed 3650 records, narrowing down to 13 articles for full-text examination. Of these, 3 retrospective cohort studies met our inclusion criteria, comparing outcomes of HA combined with NSF to NSF alone. The HA plus NSF group tended to exhibit lower rates of CSF leakage compared to the NSF alone group. Similarly, the rate of reconstruction-associated complication was also lower in the HA plus NSF group than in the control group. Skull base reconstruction using HA and NSF can be an effective way to minimize CSF leakage without major complications.
A series of ortho isomers of meso tetrakis N-alkylpyridylporphyrins (alkyl being methyl, ethyl, n-propyl, n-butyl, n-hexyl, and n-octyl) and their Mn(III) complexes were synthesized and characterized by elemental analysis, uv/vis spectroscopy, electrospray ionization mass spectrometry and electrochemistry. An increase in the number of carbon atoms in the alkyl chains from 1 to 8 is accompanied by an increase in: (a) lipophilicity measured by the chromatographic retention factor, Rf; (b) metal-centered redox potential, E1/2 from +220 to +367 mV vs NHE, and (c) proton dissociation constant, pKa2 from 10.9 to 13.2. A linear correlation was found between E1/2 and Rf of the Mn(III) porphyrins and between the pKa2 and Rf of the metal-free compounds. As the porphyrins become increasingly more lipophilic, the decrease in hydration disfavors the separation of charges, while enhancing the electron-withdrawing effect of the positively charged pyridyl nitrogen atoms. Consequently, the E1/2 increases linearly with the increase in pKa2, a trend in porphyrin basicity opposite from the one we previously reported for other water-soluble Mn(III) porphyrins. All of these Mn(III) porphyrins are potent catalysts for superoxide dismutation (disproportionation). Despite the favorable increase of E1/2 with the increase in chain length, the catalytic rate constant decreases from methyl (log kcat = 7.79) to n-butyl, and then increases such that the n-octyl is as potent an SOD mimic as are the methyl and ethyl compounds. The observed behavior originates from an interplay of hydration and steric effects that modulate electronic effects.
The invention relates to food additive powder for reducing blood sugar, losing weight and protecting diabetic organs, and a preparation method and application thereof, belonging to the technical field of functional food with homology of medicine and food. The technical scheme is as follows: the components by mass portion are as follows: 10-30 parts of fermented sweet buckwheat flour, 5-15 parts of fried broom corn millet flour, 3-7 parts of grape seed extract, 3-5 parts of rutin and 3-5 parts of chitosan. The product is applied to db/db mouse feed, and the effects of reducing blood sugar, losing weight and inhibiting the damage of main organs of diabetic mice are observed. The food of the invention has good effects of reducing blood sugar, losing weight and reducing the organ damage of diabetic mice. Can obviously improve the general mental state of the mouse and the abnormal change of the tissue structure of the liver and the kidney, and does not find any toxic reaction. The invention has the characteristics of good curative effect, rich nutrition, good taste, convenient application and the like.
Bronchial drainage session with the PEP device consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique. This cycle is repeated at least three times. The maximum number of cycles is five considering the need. The size of the applied expiratory resistance is selected individually. The pressure is 10-20 cmH2O during exhalation. Duration of the session: 10 - 20 min. Duration of the program: 4 days. Frequency: twice a day.
The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
This is a randomised placebo-controlled trial including 500 otherwise healthy moderate-late preterm infants. Participants will receive bacterial lysate (OM-85/Broncho-Vaxom, 3,5mg) or placebo powder for ten days each month, from 6-10 weeks after birth until 12 months after birth. At 12 months, parents of participants are asked to join in Protea-2. If they do, participants in the treatment arm of year 1 are randomised again over placebo and OM-85 and treated until the age of 24 months. Clinical data will be continuously collected by e-Health and 3 (possibly digital) study visits; with optional biological sampling and lung function at baseline, 6 and 12 months. And in case of participation in Protea-2 also at 24 months.

Main study parameters are doctor diagnosed lower RTI and wheezing episodes in the first year of life. Biological sampling will allow investigation of immune maturation, as well as microbiome development in the respiratory tract and gut. Also, biomarkers for risk-group selection and/or treatment success will be examined.